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Cholesterol ester transfer protein inhibition by TA-8995 in 
patients with mild dyslipidaemia (TULIP): a randomised, 
double-blind, placebo-controlled phase 2 trial
G Kees Hovingh, John J P Kastelein, Sander J H van Deventer, Patrick Round, John Ford, Danish Saleheen, Daniel J Rader, H Bryan Brewer, Philip J Barter
Summary
Background Dyslipidaemia remains a signifi cant risk factor for cardiovascular disease and additional lipid-modifying 
treatments are warranted to further decrease the cardiovascular disease burden. We assessed the safety, tolerability and 
effi  cacy of a novel cholesterol esterase transfer protein (CETP) inhibitor TA-8995 in patients with mild dyslipidaemia.
Methods In this randomised, double-blind, placebo-controlled, parallel-group phase 2 trial, we recruited patients 
(aged 18–75 years) from 17 sites (hospitals and independent clinical research organisations) in the Netherlands and 
Denmark with fasting LDL cholesterol levels between 2·5 mmol/L and 4·5 mmol/L, HDL cholesterol levels between 
0·8 and 1·8 mmol/L and triglyceride levels below 4·5 mmol/L after washout of lipid-lowering treatments. Patients 
were randomly allocated (1:1) by a computer-generated randomisation schedule to receive one of the following nine 
treatments: a once a day dose of 1 mg, 2·5 mg, 5 mg, or 10 mg TA-8995 or matching placebo; 10 mg TA-8995 plus 
20 mg atorvastatin; 10 mg TA-8995 plus 10 mg rosuvastatin or 20 mg atorvastatin or 10 mg rosuvastatin alone. We 
overencapsulated statins to achieve masking. The primary outcome was percentage change in LDL cholesterol and 
HDL cholesterol from baseline at week 12, analysed by intention to treat. This study is registered with ClinicalTrials.
gov, number NCT01970215.
Findings Between Aug 15, 2013, and Jan 10, 2014, 364 patients were enrolled. At week 12, LDL cholesterol levels were 
reduced by 27·4% in patients assigned to the 1 mg dose, 32·7% in patients given the 2·5 mg dose, 45·3% in those 
given the 5 mg dose, and 45·3% in those given the 10 mg dose (p<0·0001). LDL cholesterol levels were reduced by 
68·2% in patients given 10 mg TA-8995 plus atorvastatin, and by 63·3% in patients given rosuvastatin plus 10 mg 
TA-8995 (p<0·0001). A daily dose of 1 mg TA-8995 increased HDL cholesterol levels by 75·8%, 2·5 mg by 124·3%, 
5 mg by 157·1%, and 10 mg dose by 179·0% (p<0·0001). In patients receiving 10 mg TA-8995 and 20 mg atorvastatin 
HDL cholesterol levels increased by 152·1% and in patients receiving 10 mg TA-8995 and 10 mg rosuvastatin by 
157·5%. We recorded no serious adverse events or signs of liver or muscle toxic eff ects.
Interpretation TA-8995, a novel CETP inhibitor, is well tolerated and has benefi cial eff ects on lipids and apolipoproteins 
in patients with mild dyslipidaemia. A cardiovascular disease outcome trial is needed to translate these eff ects into a 
reduction of cardiovascular disease events.
Funding Dezima.
Introduction
Robust evidence exists showing that reducing the 
concentration of LDL chol esterol results in a signifi cant 
reduction in the risk of having a major cardiovascular 
event.1 For every 1·0 mmol/L reduction in LDL 
cholesterol, the risk of having a cardiovascular event falls 
by roughly 22%.1 However, many people remain at an 
unacceptably high risk of having a future cardiovascular 
event despite treatment with optimum doses of eff ective 
statins and other lipid lowering treatments. Although the 
residual risk relates (at least partly) to factors other than 
plasma lipids, in many patients the concentration of LDL 
cholesterol remains high despite statin treatment. This 
fi nding has stimulated a major eff ort to develop drugs 
that provide additional lowering of LDL cholesterol when 
coadministered with a statin.
Several LDL cholesterol-lowering strategies are being 
investigated, and inhibitors of cholesteryl ester transfer 
protein (CETP), by virtue of their eff ect on the transfer 
of cholesterol into atherogenic LDL particles,2 reduce 
LDL cholesterol levels.
Initial attempts to show cardioprotective eff ects of 
CETP inhibition with torcetrapib and dalcetrapib in 
human beings have failed.3,4 Nevertheless, the hypothesis 
of a benefi cial eff ect of CETP lowering is being tested in 
two large clinical outcome trials (REVEAL [NCT01252953] 
and ACCELERATE [NCT01687998]) in which 
investigators are studying CETP inhibitors that do not 
possess the adverse off -target eff ects of torcetrapib.
In a phase 1 study5 in human beings, TA-8995, a novel 
inhibitor of CETP, exerted potent eff ects on both 
pro-atherogenic and anti-atherogenic lipoprotein particles, 
without the off -target eff ects of torcetrapib.
We aimed to assess the safety and effi  cacy of TA-8995 
as monotherapy and combined with statins in patients 
with mild dyslipidaemia.
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Methods
Study design and participants
In this randomised, double-blind, placebo-controlled, 
parallel-group phase 2 trial, we recruited men and 
women (aged 18–75 years) from 17 sites (hospitals and 
independent clinical research organisations) in the 
Netherlands and Denmark with fasting LDL cholesterol 
levels between 2·5 mmol/L and 4·5 mmol/L, HDL 
cholesterol levels between 0·8 mmol/L and 1·8 mmol/L 
and triglyceride levels below 4·5 mmol/L after run-in, or 
washout of previous lipid-lowering treatments. Key 
exclusion criteria included clinical manifestations of 
athero sclerotic vascular disease, type 1 diabetes, 
uncontrolled type 2 diabetes (haemoglobin A1c ≥8%), 
uncontrolled hyper tension, history of hyper aldo-
steronism, active muscle disease or persistent creatine 
kinase more than three times the upper limit of normal, 
clinically signifi cant renal or hepatic dysfunction, or evid-
ence of any other clinically signifi cant non-cardiac 
disease.
The study was in compliance with the ethical principles 
in the Declaration of Helsinki, the International 
Conference on Harmonisation/Good Clinical Practice, 
and appropriate regulatory requirements. The protocol 
was reviewed and approved by the Institutional Review 
Board of each participating centre and each patient 
provided written informed consent.
Randomisation and masking
We randomly assigned (1:1) patients to receive one of the 
following nine treatments: 1 mg, 2·5 mg, 5 mg, or 10 mg 
TA-8995 or matching placebo; 10 mg TA-8995 plus 20 mg 
atorvastatin, 10 mg TA-8995 plus 10 mg rosuvastatin, 
20 mg atorvastatin, or 10 mg rosuvastatin. Patients were 
assigned to treatment regimens with a computer-
generated randomisation schedule coordinated by a 
centralised computer system. Treatment allocation 
process was by minimisation. Trial treatments were 
supplied as TA-8995 capsules and matching placebos. 
Additionally, atorvastatin and rosuvastatin were 
overencapsulated and all patients whose treatment did 
not include a statin were also given a matching placebo-
statin to maintain masking. During the trial, the patients 
and all trial-related personnel were masked to individual 
results of fasting lipid profi le measurements, with the 
exception of safety alerts which were sent to an 
independent safety group handling all safety-related 
issues during the trial.
Figure 1: Trial profi le
The primary effi  cacy dataset included all patients who received at least one dose of study drug and had lipid measurements at baseline and week 12. All patients who 
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Procedures
The TULIP study comprised a screening visit, followed 
by a run-in phase of 4 weeks (or 6 weeks for patients 
who needed washout of lipid-lowering treatment). All 
treatments were to be taken once a day with food for 
12 weeks. During the double-blind treatment phase, 
visits were done at baseline (week 0) and at weeks 4, 8, 
and 12. Follow-up visits were done 2 and 8 weeks after 
the end of treatment. A data safety monitoring board 
ensured an independent review of safety-related 
variables during the trial. The appendix shows details of 
the assay methods.






























plus 10 mg 
TA-8995 
(n=41)
Age (years) 64·4 (6·6) 65·8 (6·3) 65·5 (6·9) 64·9 (7·8) 66·0 (5·0) 64·0 (9·4) 63·3 (9·1) 64·7 (8·0) 63·8 (6·1)
Sex (male) 38 (95%) 32 (78%) 33 (81%) 35 (88%) 31 (78%) 28 (70%) 35 (88%) 30 (73%) 35 (85%)
BMI (kg/m²) 26·0 (1·8) 26·4 (2·7) 25·6 (2·8) 26·3 (2·7) 25·9 (2·6) 25·7 (2·4) 26·0 (2·8) 26·1 (2·7) 26·3 (3·4)
Ethnic origin
White 40 (100%) 41 (100%) 41 (100%) 39 (98%) 38 (95%) 39 (98%) 39 (98%) 40 (98%) 40 (98%)
Other 0 (0%) 0 (0%) 0 (0%) 1 (3%) 2 (5%) 1 (3%) 1 (3%) 1 (2%) 1 (2%)
Smoking status
Current smoker 6 (15%) 2 (5%) 6 (15%) 5 (13%) 7 (18%) 2 (5%) 5 (13%) 4 (10%) 8 (20%)
Non-smoker 16 (40%) 20 (49%) 18 (44%) 21 (53%) 13 (33%) 18 (45%) 12 (30%) 12 (29%) 16 (39%)
Past smoker 18 (45%) 19 (46%) 17 (42%) 14 (35%) 20 (50%) 20 (50%) 23 (58%) 25 (61%) 17 (42%)
Type 2 diabetes 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3%) 0 (0%) 1 (3%) 2 (5%) 1 (2%)
Data are mean (SD) or n (%).
Table 1: Baseline characteristics
N Baseline Week 12 Absolute change from baseline 
at week 12
% change from baseline 
at week 12








Placebo 36 3·8 (0·5) 3·7 (0·5) –0·05, –0·09 (–0·34 to 0·22) 0·8 (–3·4 to 4·9) NA NA
1 mg TA-8995 36 3·6 (0·6) 2·6 (0·6) –0·98, –1·03 (–1·36 to –0·55) –27·4 (–31·5 to –23·2) <0·0001 NA
2·5 mg TA-8995 38 3·6 (0·5) 2·4 (0·7) –1·15, –1·17 (–1·52 to –0·64) –32·7 (–36·8 to –28·6) <0·0001 NA
5 mg TA-8995 39 3·5 (0·6) 1·9 (0·5) –1·62, –1·66 (–2·04 to –1·21) –45·3 (–49·3 to –41·3) <0·0001 NA
10 mg TA-8995 35 3·5 (0·6) 1·9 (0·5) –1·62, –1·66 (–1·92 to –1·14) –45·3 (–49·4 to –41·1) <0·0001 NA
20 mg atorvastatin 37 3·8 (0·4) 2·0 (0·4) –1·77, –1·71 (–2·17 to –1·50) –45·4 (–49·5 to –41·3) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 3·5 (0·6) 1·1 (0·4) –2·37, –2·38 (–2·82 to –2·09) –68·2 (–72·3 to –64·2) NA <0·0001
10 mg rosuvastatin 38 3·7 (0·6) 2·0 (0·4) –1·72, –1·71 (–2·12 to –1·29) –45·3 (–49·4 to –41·3) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 37 3·6 (0·6) 1·3 (0·4) –2·26, –2·26 (–2·54 to –2·02) –63·3 (–67·4 to –59·2) NA <0·0001
HDL cholesterol (mmol/L)
Placebo 37 1·3 (0·3) 1·4 (0·3) 0·02, 0·03 (–0·08 to 0·13) 2·2 (–8·0 to 12·4) NA NA
1 mg TA-8995 37 1·3 (0·2) 2·4 (0·5) 1·02, 1·03 (0·78 to 1·16) 75·8 (65·5 to 86·1) <0·0001 NA
2·5 mg TA-8995 38 1·4 (0·3) 3·0 (0·7) 1·66, 1·65 (1·40 to 1·97) 124·3 (114·0 to 134·5) <0·0001 NA
5 mg TA-8995 39 1·3 (0·2) 3·3 (0·5) 2·01, 1·99 (1·68 to 2·28) 157·1 (147·0 to 167·1) <0·0001 NA
10 mg TA-8995 35 1·3 (0·3) 3·6 (0·6) 2·30, 2·17 (1·94 to 2·59) 179·0 (168·6 to 189·4) <0·0001 NA
20 mg atorvastatin 37 1·4 (0·2) 1·4 (0·3) 0·01, 0·03 (–0·10 to 0·08) 5·7 (–4·7 to 16·0) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 1·3 (0·3) 3·3 (0·5) 1·94, 1·98 (1·74 to 2·18) 152·1 (141·9 to 162·2) NA <0·0001
10 mg rosuvastatin 38 1·3 (0·3) 1·4 (0·3) 0·07, 0·04 (–0·06 to 0·23) 7·1 (–3·0 to 17·2) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 1·4 (0·3) 3·4 (0·5) 2·07, 2·04 (1·76 to 2·38) 157·5 (147·4 to 167·6) NA <0·0001
Data are n; mean (SD); mean, median (25–75th centiles); or least-squares mean (95% CI). N includes all patients who received at least one dose of study drug and had both baseline and week 12 data for each 
parameter.
Table 2: Summary of primary endpoints
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Outcomes
The coprimary effi  cacy outcome parameters were percent 
change in LDL cholesterol and HDL cholesterol levels at 
week 12 compared with baseline. Secondary effi  cacy 
assessments included fasted total cholesterol, triglycerides, 
apolipoproteins A-I, B, and E and lipoprotein(a). Additional 
endpoints included CETP plasma concentrations, CETP 
activity, and homeostatic model assessment of insulin 
resistance (HOMA-IR). Cholesterol effl  ux capacity, an 
exploratory outcome, was measured according to the 
method described by Khera and colleagues6,7 in patients 
receiving either placebo, 1 mg TA-8995, 10 mg TA-8995, or 
10 mg TA-8995 plus 10 mg rosuvastatin.
Safety was assessed throughout the trial by monitoring 
adverse events, concomitant drug use, 12-lead electro-
cardiographs, vital signs, laboratory safety assessments, 
N Baseline Week 12 Absolute change from baseline at 
week 12
% change from 
baseline at week 12









Placebo 37 1·4 (0·6) 1·3 (0·6) –0·07, –0·12 (–0·36 to 0·07) –3·0 (–13·3, 7·4) NA NA
1 mg TA-8995 37 1·4 (0·5) 1·1 (0·4) –0·30, –0·19 (–0·46 to –0·03) –17·5 (–27·9, –7·1) 0·0524 NA
2·5 mg TA-8995 38 1·4 (0·8) 1·2 (0·4) –0·26, –0·12 (–0·43 to 0·05) –11·8 (–22·1, –1·5) 0·2347 NA
5 mg TA-8995 39 1·7 (1·0) 1·3 (0·5) –0·38, –0·14 (–0·64 to 0·06) –7·6 (–17·8, 2·5) 0·5274 NA
10 mg TA-8995 35 1·7 (0·7) 1·5 (0·9) –0·19, –0·12 (–0·59 to 0·16) –5·7 (–16·3, 4·9) 0·7179 NA
20 mg atorvastatin 37 1·4 (0·5) 1·0 (0·3) –0·39, –0·34 (–0·51 to –0·25) –25·2 (–35·6, –14·7) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 1·3 (0·6) 1·0 (0·4) –0·32, –0·24 (–0·49 to 0·02) –18·0 (–28·3, –7·7) NA 0·3355
10 mg rosuvastatin 38 1·6 (0·7) 1·3 (1·2) –0·28, –0·38 (–0·69 to –0·09) –14·9 (–25·2, –4·7) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 1·4 (0·6) 1·0 (0·3) –0·34, –0·30 (–0·58 to –0·01) –11·5 (–21·7, –1·2) NA 0·6408
Total cholesterol (mmol/L)
Placebo 37 5·8 (0·5) 5·8 (0·6) –0·03, –0·05 (–0·34 to 0·28) 1·1 (–2·6, 4·7) NA NA
1 mg TA-8995 37 5·6 (0·7) 5·5 (0·9) –0·11, –0·13 (–0·52 to 0·36) –2·0 (–5·6, 1·7) 0·2507 NA
2·5 mg TA-8995 38 5·6 (0·7) 5·9 (1·0) 0·31, 0·43 (–0·31 to 0·98) 5·8 (2·1, 9·4) 0·0756 NA
5 mg TA-8995 39 5·6 (0·7) 5·7 (0·8) 0·11, 0·16 (–0·39 to 0·57) 2·2 (–1·3, 5·8) 0·6560 NA
10 mg TA-8995 35 5·7 (0·6) 6·1 (0·7) 0·44, 0·47 (–0·15 to 0·99) 8·5 (4·8, 12·1) 0·0056 NA
20 mg atorvastatin 37 5·9 (0·5) 3·9 (0·5) –1·97, –2·02 (–2·49 to –1·53) –31·7 (–35·4, –28·0) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 5·5 (0·7) 4·8 (0·6) –0·69, –0·77 (–1·12 to –0·36) –13·2 (–16·8, –9·6) NA <0·0001
10 mg rosuvastatin 38 5·8 (0·7) 4·0 (0·5) –1·88, –1·90 (–2·28 to –1·58) –30·7 (–34·3, –27·1) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 5·6 (0·7) 5·2 (0·8) –0·46, –0·47 (–0·90 to 0·05) –8·2 (–11·8, –4·6) NA <0·0001
Apolipoprotein A-1 (g/L)
Placebo 37 1·4 (0·2) 1·5 (0·2) 0·02, 0·05 (–0·11 to 0·12) 2·5 (–2·4, 7·4) NA NA
1 mg TA-8995 37 1·4 (0·2) 1·9 (0·3) 0·45, 0·45 (–0·28 to 0·61) 31·2 (26·2, 36·1) <0·0001 NA
2·5 mg TA-8995 38 1·5 (0·2) 2·2 (0·4) 0·69, 0·73 (0·49 to 0·85) 49·0 (44·1, 53·9) <0·0001 NA
5 mg TA-8995 39 1·4 (0·2) 2·2 (0·3) 0·81, 0·82 (0·64 to 0·95) 57·5 (52·7, 62·3) <0·0001 NA
10 mg TA-8995 35 1·4 (0·2) 2·3 (0·2) 0·90, 0·86 (0·73 to 1·03) 63·4 (58·3, 68·4) <0·0001 NA
20 mg atorvastatin 37 1·5 (0·2) 1·5 (0·2) –0·03, –0·04 (–0·15 to 0·10) 0·8 (–4·2, 5·8) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 1·4 (0·2) 2·1 (0·2) 0·74, 0·72 (0·62 to 0·91) 52·7 (47·8, 57·5) NA <0·0001
10 mg rosuvastatin 38 1·4 (0·2) 1·5 (0·2) 0·04, 0·05 (–0·06 to 0·15) 4·3 (–0·6, 9·2) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 1·4 (0·2) 2·2 (0·2) 0·77, 0·75 (0·66 to 0·88) 55·8 (50·9, 60·6) NA <0·0001
Apolipoprotein B (g/L)
Placebo 37 1·0 (0·1) 1·0 (0·1) –0·01, –0·02 (–0·09 to 0·06) 1·1 (–2·5, 4·7) NA NA
1 mg TA-8995 37 1·0 (0·2) 0·8 (0·1) –0·20, –0·18 (–0·31 to –0·11) –20·0 (–23·6, –16·4) <0·0001 NA
2·5 mg TA-8995 38 1·0 (0·2) 0·7 (0·1) –0·25, –0·23 (–0·33 to –0·14) –24·6 (–28·2, –21·0) <0·0001 NA
5 mg TA-8995 39 1·0 (0·2) 0·7 (0·1) –0·35, –0·37 (–0·45 to –0·24) –33·6 (–37·1, –30·1) <0·0001 NA
10 mg TA-8995 35 1·0 (0·2) 0·6 (0·1) –0·35, –0·34 (–0·44 to –0·21) –33·7 (–37·3, –30·0) <0·0001 NA
20 mg atorvastatin 37 1·0 (0·1) 0·6 (0·1) –0·40, –0·41 (–0·47 to –0·31) –37·4 (–41·0, –33·8) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 1·0 (0·2) 0·5 (0·1) –0·51, –0·51 (–0·61 to –0·41) –50·1 (–53·7, –46·6) NA <0·0001
10 mg rosuvastatin 38 1·0 (0·1) 0·7 (0·1) –0·37, –0·36 (–0·44 to –0·27) –34·5 (–38·0, –30·9) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 1·0 (0·1) 0·5 (0·1) –0·47, –0·45 (–0·53 to –0·39) –46·3 (–49·9, –42·8) NA <0·0001
(Table 3 continues on next page)
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and physical examinations. Additional safety assess-
ments included plasma aldosterone, salivary cortisol, 
high-sensitivity C-reactive protein, and endothelin-1 con-
centrations. Blood samples were also collected for 
pharmacokinetic analysis.
Statistical analysis
The primary effi  cacy analysis of the percent change in 
HDL cholesterol and LDL cholesterol from baseline to 
week 12 was done with a restricted maximum likelihood 
mixed model for repeated measures approach. Analysis 
included fi xed categorical eff ects of treatment, visit and 
treatment-by-visit interaction, and a continuous fi xed 
covariate for baseline HDL cholesterol or LDL cholesterol 
score. Least-squares means, standard errors and 
two-tailed 95% confi dence intervals for each treatment 
group and for pairwise comparisons between TA-8995 
doses and placebo, between TA-8995 plus atorvastatin 
and atorvastatin alone, and between TA-8995 plus 
rosuvastatin and rosuvastatin alone were provided. 
Because there were two coprimary effi  cacy variables, we 
used a closed testing procedure to control the family-wise 
error. No interim analyses were planned or undertaken.
The sample size of 37 completed patients per 
treatment group was intended to provide 88% power to 
detect a 22·5% (standard deviation [SD] 30%) increase 
in HDL cholesterol compared with statin alone. This 
sample size with an assumed 10% (SD 15%) greater 
decrease in LDL cholesterol for the investigational 
product compared with placebo was expected to provide 
a power of 80%. All tests were two-sided with a 
signifi cance of 0·05. To allow for a 10–15% dropout rate, 
378 patients were planned. All analyses were done with 
SAS (version 9.2).
The trial protocol was registered on ClinicalTrials.gov, 
number NCT01970215.
Role of the funding source
The funder was involved in the design of the study and in 
collection, management, and analysis of the data, in 
conjunction with the steering committee. The initial 
draft of the report was prepared by PR and PJB. GKH in 
conjunction with the other authors had the main 
responsibility for the decision to submit for publication. 
The authors vouch for the accuracy and completeness of 
the data and analyses as presented.
Results
Between August, 2013, and July, 2014, 364 patients were 
randomly assigned and received at least one dose of 
study treatment, and 337 (93%) completed the trial 
(fi gure 1). Primary outcome data (LDL cholesterol and 
N Baseline Week 12 Absolute change from baseline at 
week 12
% change from 
baseline at week 12





TA-8995 + statin 
versus statin 
alone
(Continued from previous page)
Apolipoprotein E (g/L)
Placebo 37 0·04 (0·01) 0·04 (0·01) 0·001, 0·000 (–0·002 to 0·003) 3·2 (–7·8, 14·3) NA NA
1 mg TA-8995 37 0·04 (0·01) 0·05 (0·02) 0·008, 0·004 (–0·001 to 0·012) 19·3 (8·2, 30·4) 0·0446 NA
2·5 mg TA-8995 38 0·04 (0·01) 0·05 (0·02) 0·012, 0·008 (0·003 to 0·018) 33·4 (22·3, 44·4) 0·0002 NA
5 mg TA-8995 39 0·04 (0·01) 0·05 (0·02) 0·012, 0·010 (0·004 to 0·024) 37·8 (27·0, 48·6) <0·0001 NA
10 mg TA-8995 35 0·04 (0·01) 0·06 (0·02) 0·020, 0·017 (0·009 to 0·028) 57·0 (45·8, 68·2) <0·0001 NA
20 mg atorva 37 0·04 (0·01) 0·03 (0·01) –0·008, –0·008 (–0·010 to –0·004) –20·7 (–31·8, –9·5) NA NA
20 mg atorva + 10 mg TA-8995 38 0·04 (0·01) 0·04 (0·02) 0·006, 0·006 (–0·005 to 0·013) 17·9 (7·0, 28·8) NA <0·0001
10 mg rosuvastatin 38 0·04 (0·01) 0·03 (0·01) –0·007, –0·007 (–0·012 to –0·002) –15·9 (–26·7, –4·9) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 0·04 (0·01) 0·06 (0·02) 0·019, 0·017 (0·008 to 0·028) 54·6 (43·7, 65·5) NA <0·0001
Lipoprotein(a) (nmol/L)
Placebo 37 51·8 (61·8) 49·4 (61·9) –2·4, –1·0 (–7 to 0) –1·8 (–10·7 to 7·2) NA NA
1 mg TA-8995 37 47·3 (55·5) 39·5 (55·4) –7·8, –5·0 (–10 to –2) –29·5 (–38·6 to –20·4) <0·0001 NA
2·5 mg TA-8995 38 44·6 (53·2) 33·6 (44·1) –11·0, –5·5 (–16 to 0) –26·7 (–35·7 to –17·7) 0·0001 NA
5 mg TA-8995 39 42·2 (54·3) 23·7 (37·7) –18·5, –11·0 (–32 to –1) –36·9 (–45·7 to –28·1) <0·0001 NA
10 mg TA-8995 35 44·4 (65·6) 27·6 (48·1) –16·8, –10·0 (–25 to 0) –33·4 (–42·5 to –24·4) <0·0001 NA
20 mg atorvastatin 37 31·6 (41·3) 30·1 (38·9) –1·5, –1·0 (–3 to 1) –3·6 (–12·7 to 5·5) NA NA
20 mg atorvastatin plus 10 mg TA-8995 38 36·6 (42·7) 28·5 (40·5) –8·1, –3·5 (–11 to 0) –25·0 (–33·8 to –16·1) NA 0·0011
10 mg rosuvastatin 38 38·8 (54·8) 37·5 (58·0) –1·3, 0·0 (–3 to 0) –7·9 (–16·8 to 1·0) NA NA
10 mg rosuvastatin plus 10 mg TA-8995 38 62·3 (74·4) 55·9 (78·6) –6·3, –3·0 (–17 to 0) –25·4 (–34·3 to –16·5) NA 0·0064
Data are n; mean (SD); mean, median (25–75th centiles); or least-squares mean (95% CI). N includes all patients who received at least one dose of study drug and had both baseline and week 12 data.
Table 3: Summary of secondary endpoints
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Figure 2: Baseline and 
week 12 data for LDL (A) and 
HDL (B)
Boxes show the 25th and 75th 
percentiles, whiskers show the 
minimum and maximum 
values, horizontal lines show 
the median, and green circles 
show the mean. The data only 
include patients who had both 
baseline and week 12 data. The 
changes from baseline for all 
active treatments showed 
signifi cant diff erences from 
placebo at week 12 
(p<0·0001).
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HDL cholesterol levels at week 12) were available in 35 to 
38 patients per treatment group. Table 1 shows baseline 
characteristics across all treatment groups. Most 
participants were white men with a mean age of 65 years 
(range 22–75). Mean baseline LDL cholesterol 
concentration was 3·60 mmol/L (SD 0·57) and HDL 
cholesterol was 1·35 mmol/L (0·26) and these did not 
diff er across treatment groups (table 1).
Table 2 shows the primary effi  cacy outcomes. At week 12, 
LDL cholesterol concentrations were reduced signifi cantly 
by 27·4% in patients who received 1 mg TA-8995, 32·7% in 
those who received the 2·5 mg dose, 45·3% in those given 
the 5 mg dose, and 45·3% in those given the 10 mg dose 
(p<0·0001 for all). A daily dose of 20 mg atorvastatin 
resulted in a 45·4% decrease in LDL cholesterol, whereas 
we noted a 68·2% decrease in patients given 10 mg TA-8995 
plus atorvastatin 20 mg (p<0·0001), which translates into 
an additional 50·2% reduction in LDL cholesterol in 
patients randomly assigned to combination therapy. We 
noted similar results in patients given 10 mg rosuvastatin 
(LDL cholesterol decrease 45·3%) or 10 mg rosuvastatin 
plus 10 mg TA-8995 (LDL cholesterol decrease of 63·3%), 
which corresponds to an additional 39·8% lowering of 
LDL cholesterol in patients given TA-8995 combined with 
rosuvastatin. Figure 2 shows the results for the primary 
outcomes. When TA-8995 was provided as monotherapy, 
95% of patients achieved an LDL cholesterol concentration 
lower than 2·5 mmol/L at both the daily 5 mg and 10 mg 
doses, whereas 65% of patients given the 5 mg dose 
achieved an LDL cholesterol concentration lower than 
1·8 mmol/L and 63% of those given the 10 mg dose.
HDL cholesterol was increased signifi cantly from 
baseline to week 12 by 75·8% in patients given 1 mg 
TA-8995 a day, 124·3% in those given 2·5 mg, 157·1% in 
those given 5 mg, and 179·0% in those given 10 mg 
(p<0·0001). We noted these eff ects at the fi rst post-
randomisation visit (week 4) and the eff ects remained 
present throughout the treatment period (data not 
shown). TA-8995 was equally eff ective when given as 
monotherapy or on top of statin treatment. HDL 
cholesterol increased by 152·1% in patients receiving 
10 mg TA-8995 combined with 20 mg atorvastatin and 
157·5% in patients receiving 10 mg TA-8995 combined 
with 10 mg rosuvastatin (p<0·0001 for both).
Table 3 shows the secondary effi  cacy outcomes. TA-8995 
had no signifi cant eff ect on plasma triglyceride or total 
cholesterol levels. However, monotherapy with TA-8995 
resulted in substantial dose-dependent increases in 
apoA-1 and apoE concentrations, all of which were 
signifi cant compared with baseline (p<0·0001), except for 
the apoE change in patients given 1 mg TA-8995 
(p=0·0446) and 2·5 mg TA-8995 (p=0·0002). Additionally, 
apoB concentrations were reduced by 20·0% to 33·7% in 
patients receiving TA-8995 as monotherapy (p<0·0001), 
whereas in patients receiving TA-8995 combined with 
atorvastatin, concentrations were reduced by 50·1% and 
in patients receiving TA-8995 combined with rosuvastatin 
apoB by 46·3% (p<0·0001).
The diff erent doses of TA-8995, either as monotherapy 
or combined with a statin resulted in reductions in 
lipoprotein(a) ranging from 26·7% to 36·9% (p<0·0064), 
whereas monotherapy with a statin resulted in reductions 
in lipoprotein(a) of 3·6% and 7·9% (table 3). Monotherapy 
with TA-8995 reduced CETP activity by up to 84·9% 
(p<0·0001; appendix).
Serum-mediated cholesterol effl  ux was measured at 
baseline and at week 12 as an exploratory outcome. We 
noted a 7% reduction in serum-mediated cell cholesterol 
effl  ux (fi gure 3) in patients given placebo. By contrast, the 
ability of serum to promote cholesterol effl  ux was 
increased by 16·9% (p<0·0001) in patients given 1 mg 
TA-8995, whereas treatment with the 10 mg dose resulted 
in a 36·7% increase in serum-mediated cholesterol effl  ux 
(p< 0·0001; fi gure 3).
TA-8995 was well tolerated and the percentage of 
patients withdrawing because of adverse events was low 
and similar across treatment groups (appendix). The most 
common adverse events in the TA-8995 monotherapy 
group were nasopharyngitis and headache. Most (122/127 
[96%]) adverse events were classifi ed as mild or moderate. 
Eight patients had serious adverse events during the study 
but none were deemed to be treatment-related. We noted 
no eff ect of TA-8995 (whether given as monotherapy or in 
combination with a statin) on any laboratory safety 
parameter including serum aldosterone, salivary cortisol, 
high sensitivity C-reactive protein or endothelin-1. We 
analysed the data for each treatment group separately and 
combined for all patients receiving TA-8995 monotherapy 
(appendix). TA-8995 had no eff ect on serum electrolyte 
concentrations or blood pressure (appendix). TA-8995 
treatment did not aff ect HOMA-IR (appendix).
The mean trough concentrations of TA-8995 were the 
same at weeks 8 and 12, which suggests that steady state 
conditions had been achieved by week 8 (data not shown). 
Figure 3: Baseline and week 12 data for serum-driven cholesterol effl  ux
Bars are means and error bars are standard deviations. The baseline data only include patients who had both 
baseline and week 12 data. The changes from baseline for all active treatments showed signifi cant diff erences from 
placebo at week 12 (*p<0·0001).
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After cessation of dosing, concentrations decreased rapidly 
and by week 20 (8 weeks after the last dose), concentrations 
of TA-8995 (given either as monotherapy or in combination 
with a statin) were less than 3% of the trough levels during 
treatment, which emphasises that TA-8995 does not 
accumulate during a 12-week dosing period.
Discussion
In this phase 2 study we showed that administration of 
TA-8995, a new CETP inhibitor, reduced LDL cholesterol 
levels by 45·3% and apoB levels by 33·7%, whereas HDL 
cholesterol levels increased by up to 179·1% and apoA-1 
levels by up to 63·4%. In combination with statins, 10 mg 
TA-8995 conferred an additional decrease of LDL 
cholesterol by 39·8% to 50·2% (panel).
CETP promotes the transfer of cholesteryl esters (the 
main form of cholesterol in plasma) from non-
atherogenic HDL particles, where they are formed, to 
particles in lipoprotein fractions (including LDL) that 
cause atherosclerosis. Inhibition of CETP blocks this 
transfer and reduces the concentration of cholesterol not 
only in LDL, but also in other atherogenic lipoproteins. 
The hypothesis that CETP inhibition might be 
antiatherogenic is supported by results of genomic 
studies showing that carriers of CETP polymorphisms 
associated with low CETP activity are at a decreased risk 
of future cardiovascular events.8,9
The ILLUMINATE study3 was the fi rst clinical trial to 
address the eff ect of lowering CETP on cardiovascular 
disease outcome. In this study, torcetrapib, a CETP 
inhibitor that reduced LDL cholesterol levels by roughly 
25% and raised HDL cholesterol levels by about 50%, did 
not reduce cardiovascular risk. In fact, torcetrapib increased 
both non-fatal and fatal cardiovascular events and also 
increased death from non-cardiovascular causes. The 
explanation for the adverse outcome is not fully understood, 
but could have been the consequence of serious off -target 
eff ects of this compound. Investigators noted a signifi cant 
increase in blood pressure in patients given torcetapib. 
Results of subsequent studies showed that torcetrapib also 
increased the synthesis and secretion of both aldosterone 
and cortisol from adrenal cortical cells in tissue culture and 
increased expression of endothelin-1 in the artery wall.10,11 
The presence of these off -target eff ects made it impossible 
to draw any meaningful conclusions regarding the possible 
antiatherogenic potential of CETP inhibition.
TA-8995 seems to be free of the adverse eff ects of 
torcetrapib and, at low doses, eff ectively reduces LDL 
cholesterol, apoB, and lipoprotein(a). The magnitude of 
the reductions induced by treatment with TA-8995 
suggests that this drug has the potential to provide 
substantial reductions in cardiovascular risk. Findings of 
previous intervention studies have shown that a 
statin-induced decrease in LDL cholesterol and apoB has 
a benefi cial eff ect on cardiovascular disease outcome12 
and the clinical relevance of non-statin induced LDL 
cholesterol lowering has recently been established in the 
IMPROVE-IT study.13 Lipoprotein(a) concentrations are 
positively associated with incident cardiovascular disease 
events, but whether lipoprotein(a) lowering results in 
cardiovascular disease risk reduction is unknown.14
Although CETP inhibitors were initially designated 
HDL cholesterol-increasing agents, TA-8995 potently 
reduces the concentrations of atherogenic lipoproteins 
such as LDL, either as monotherapy or in combination 
with statin treatment. The major increase in concentrations 
of HDL cholesterol and apoA-1 with TA-8995 might have 
an additional benefi cial eff ect. The role of HDL cholesterol 
in cardiovascular disease risk is not completely understood 
and it remains to be established whether a therapeutic 
increase of HDL cholesterol and HDL particle numbers 
will translate into a reduced cardiovascular disease risk.15 
Dalcetrapib, a rather weak CETP inhibitor that increased 
HDL cholesterol concentrations by about 30% and had no 
eff ect on LDL cholesterol levels, was not associated with 
cardiovascular events or cardiovascular-related adverse 
events.4
The failure of dalcetrapib could have been the 
consequence of the inability of this agent to reduce the 
levels of LDL cholesterol or to suffi  ciently stimulate 
cholesterol effl  ux. Cholesterol effl  ux has been studied by 
Ray and coworkers16 who noted that total cholesterol effl  ux 
capacity, assessed by the same method used in the present 
TULIP trial, increased by 9·5% in patients randomly 
assigned to receive 600 mg dalcetrapib once a day for 
4 weeks. In patients given evacetrapib (at a dose range of 
30–500 mg per day) the mean cholesterol effl  ux increased 
by 28%.17 A daily dose of 10 mg TA-8995 resulted in a 
36·7% increase in the ability of serum to promote cell 
cholesterol effl  ux. Recent evidence that cholesterol effl  ux 
capacity has a strong inverse correlation with incident 
cardiovascular events suggests that this property of 
TA-8995 might provide additional protection against 
Panel: Research in context
Systematic review
In December, 2014, we searched Pubmed to identify studies published since 2006 in any 
language on CETP, cardiovascular disease, and (novel) therapeutic agents. The following 
terms were used: “CETP AND treatment”, and “dyslipidemia AND randomised controlled 
trial”. We only included studies in human beings.
Interpretation
Many patients do not reach optimum LDL cholesterol levels despite a maximally tolerated 
dose of statins. Further LDL cholesterol lowering is warranted in these individuals and CETP 
inhibition causes such an eff ect. Our fi ndings show that TA-8995, a novel CETP inhibitor, has 
a benefi cial eff ect on lipids and lipoproteins; LDL cholesterol decreased by 45·3% and apoB 
levels by 33·7%, whereas HDL cholesterol concentrations increased by up to 179·1% and 
apoA-I by 63·4%. Lastly, cholesterol effl  ux capacity increased by 36·7% in patients randomly 
assigned to 10 mg TA-8995. All these eff ects were similar in patients on monotherapy or in 
combination with a statin. No related serious adverse events were reported and the drug 
was well tolerated. These fi ndings are important because they provide clinicians with the 
evidence that CETP inhibition with TA-8995 is an eff ective LDL cholesterol lowering and HDL 
cholesterol increasing treatment with the aim to prevent cardiovascular disease.
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cardiovascular events.18 However, the hypothesis that a 
therapeutic increase of cholesterol effl  ux aff ects 
cardiovascular outcome remains to be validated in clinical 
studies. It also needs to be established whether a selected 
patient group characterised by an untoward 
cardiometabolic background (ie, patients with diabetes 
with high CETP) might diff erentially benefi t from CETP 
inhibitor treatment.
CETP inhibitors are lipophilic by nature and it has 
been recently reported that anacetrapib is retained in 
adipose tissue and might remain detectable in serum 
years after discontinuation of dosing.19 By contrast, 
TA-8995 is not retained in adipose tissue and is rapidly 
eliminated after discontinuation of dosing. Furthermore, 
TA-8995 was not detected in fat or liver tissue after 
9 months chronic dosing of cynomolgus monkeys at a 
supratherapeutic dose (data not shown).
In conclusion, we report the eff ects of a new CETP 
inhibitor that potently lowers the concentrations of LDL 
cholesterol, apoB, non-HDL cholesterol, and 
lipoprotein(a) either as monotherapy or in combination 
with a statin. As a potential additive benefi cial eff ect, 
TA-8995 induces a signifi cant increase of plasma apoA-I 
concentrationss and a substantial increase in the ability 
to promote cholesterol effl  ux. The translation of the 
antiatherogenic potential of TA-8995 recorded in this 
study into a reduction of future cardiovascular events 
warrants formal testing in a cardiovascular outcome trial.
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